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ORIGINAL ARTICLE
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Summary. Background: Integrin-linked kinase (ILK) and
its associated complex of proteins are involved in many
cellular activation processes, including cell adhesion and
integrin signaling. We have previously demonstrated that
mice with induced platelet ILK deficiency show reduced
platelet activation and aggregation, but only a minor
bleeding defect. Here, we explore this apparent disparity
between the cellular and hemostatic phenotypes. Methods:
The impact of ILK inhibition on integrin aIIbb3 activation
and degranulation was assessed with the ILK-specific
inhibitor QLT0267, and a conditional ILK-deficient
mouse model was used to assess the impact of ILK defi-
ciency on in vivo platelet aggregation and thrombus for-
mation. Results: Inhibition of ILK reduced the rate of
both fibrinogen binding and a-granule secretion, but was
accompanied by only a moderate reduction in the maxi-
mum extent of platelet activation or aggregation in vitro.
The reduction in the rate of fibrinogen binding occurred
prior to degranulation or translocation of aIIbb3 to the
platelet surface. The change in the rate of platelet activa-
tion in the absence of functional ILK led to a reduction
in platelet aggregation in vivo, but did not change the size
of thrombi formed following laser injury of the cremaster
arteriole wall in ILK-deficient mice. It did, however,
result in a marked decrease in the stability of thrombi
formed in ILK-deficient mice. Conclusion: Taken together,
the findings of this study indicate that, although ILK is
not essential for platelet activation, it plays a critical role
in facilitating rapid platelet activation, which is essential
for stable thrombus formation.
Keywords: embolism; integrin alpha-IIb beta-3;
integrin-linked kinase; platelets; thrombus.
Introduction
Integrin-linked kinase (ILK) was identified for its interac-
tion with the cytoplasmic tail of b-integrin subunits and
its serine/threonine kinase activity, which is upregulated
by the stimulation of platelets [1,2]. ILK functions as an
adaptor protein, binding a number of focal adhesion
(FA) proteins [3,4], including, but not restricted to,
PINCH [5,6] and parvin [7,8], to form the ILK–PINCH–
parvin (IPP) complex [9]. The IPP complex promotes
integrin clustering and the generation of FA complexes,
providing a structural link between the extracellular
matrix and the cytoskeleton, and an array of signaling
events [2,10–13]. ILK is important in a large range of tis-
sue types and cellular responses that depend on integrin
clustering and the formation of FAs [8,11,14–17]. In
platelets, where integrins have a vital role in hemostasis,
by facilitating adhesion to sites of damage and platelet–
platelet interactions, ILK interacts with, and regulates the
function of, b1 and b3 integrin subunits [18,19].
Mice with induced ILK deficiency show reduced plate-
let activation and aggregation, but only a minor bleeding
defect [14]. This disparity between the cellular and gross
hemostatic phenotypes may result from a number of fac-
tors. Our previous work showed that ILK deficiency
reduced platelet aggregation but that this effect had a
temporal component, with the inhibition being greater at
90 s than at 300 s poststimulation [14]. Given the
dynamic nature of thrombus formation, it seems intuitive
that the rate of platelet activation will have a critical role
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in regulating thrombus development; however, given the
lack of bleeding in these mice, it is possible that this sub-
tle cellular phenotype is overcome in vivo and does not
greatly alter thrombus formation.
Here, we explored this apparent disparity between the
cellular and hemostatic phenotypes by using an ILK-defi-
cient mouse model and the ILK inhibitor QLT0267 to
investigate ILK-mediated regulation of the platelet
response to stimuli and the impact of this on thrombus
formation in vivo. We show that ILK plays a critical role
in regulating the rate of platelet activation, and that this
is essential for stable thrombus formation.
Materials and methods
Platelet aggregation
Systemically inducible ILK-deficient mice were generated
as previously reported [14,20]. LoxP-flanked ILK trans-
genic mice containing a Cre-transgene under control of
the Mx1 promoter were generate and, in all cases, litter-
mate ILK(+/+): MxCre were used as the control (Ctrl).
Mice were given an intraperitoneal injection of 300 mg of
poly(I)-poly(C) 8 days prior to experiments, after which
ILK could not be detected in knockout (KO) mouse
platelets [14]. Platelets were prepared from mouse whole
blood by differential centrifugation, and aggregation was
measured in an optical aggregometer following stimula-
tion with collagen (100 lg mL1) at 37 °C [14].
For aggregation studies on human blood, platelets were
prepared from healthy donors by differential centrifuga-
tion [21], and stimulated with collagen (10 lg mL1), in
the presence of QLT0267 (1 lM) (QLT, Vancouver, BC,
Canada) or dimethylsulfoxide (DMSO) (0.025% v/v)
vehicle control. Aggregation was measured in an optical
aggregometer at 37 °C.
Clot retraction
Clot retraction was measured by mixing human platelet-
rich plasma (PRP) (200 lL), red blood cells (5 lL) and
QLT0267 (1 lM) or DMSO (0.025% v/v) vehicle control
with modified Tyrodes–Hepes buffer to a final volume of
1 mL [22]. Clotting was initiated with thrombin
(1 U mL1), and a sealed glass capillary was placed at
the center of the glass test tube, around which the clot
formed. Clots were removed from the tube after 1.5 h
and 3 h, and superficial liquid was removed from the sur-
face before the clot was pushed from the glass capillary
liquid and weighed.
Flow cytometry
Fibrinogen binding to platelets from KO or Ctrl mice in
the presence of QLT0267 was measured by diluting PRP
in Hepes-buffered saline (HBS) containing fluorescein
isothiocyanate (FITC)–anti-fibrinogen antibodies (Dako,
Ely, UK) and cross-linked collagen-related peptide (CRP-
XL; monomeric sequence GCI[GPO]10GCOG), prepared
as previously described [23] (0.5 lg mL1, 1 lg mL1,
and 2 lg mL1). Reactions were stopped after 45 s, 90 s
and 300 s by 100-fold dilution in 0.2% formyl saline, and
analyzed on an Accuri C6 flow cytometer (BD, Oxford,
UK).
For time-resolved flow cytometry experiments measur-
ing fibrinogen binding, P-selectin exposure, and calcium
flux, human PRP was diluted in HBS containing either
FITC–anti-fibrinogen antibodies (Dako) and phycoery-
thrin–anti-P-selectin antibodies (BD), or Fluo-4 NW dye
(Invitrogen, Paisley, UK), together with QLT0267 (1 lM)
or DMSO (0.025% v/v) vehicle control. All reagents were
dialyzed prior to use to remove azide. Samples were
transferred to a 96-well plate on an Accuri C6 flow
cytometer (BD) modified to maintain the plate at 37 °C,
and stimulated during data acquisition with CRP-XL
(1 lg mL1), ADP (1 9 106 M) or thrombin (0.3 U mL1)
in the presence of Gly-Pro-Arg-Pro peptide (Sigma,
Poole, UK). Data were acquired for 300 s at approxi-
mately one platelet per 1 ms, and analyzed with R (www.
r-project.org) by calculating median fluorescence intensity
(MFI) every 100 ms and fitting a LOESS curve to this,
from which the maximum platelet response and the rate
of platelet response were derived.
For time-resolved flow cytometry experiments measur-
ing surface expression of integrin aIIbb3, human PRP was
diluted in HBS, maintained at 37 °C, stimulated with
CRP-XL (1 lg mL) for 15–300 s, and then fixed with an
equal volume of 4% formyl saline. Fixed platelets were
washed twice with HBS, and then incubated with anti-b3
antibodies (Dako) for 20 min, and for a further 20 min
with Alexa Fluor 647-labeled goat anti-mouse secondary
antibodies (Life Technologies, Paisley, UK).
In vivo platelet aggregation
In vivo aggregation of radiolabeled platelets was assessed
by measuring the percentage change in radioactive counts
in the pulmonary vascular bed following the injection of
collagen into the femoral vein of Ctrl/KO mice [24].
Blood was collected into acidified citrate–dextrose solu-
tion from terminally anesthetized (urethane [25% w/v] at
10 lL g1 intraperitoneal) donor mice by cardiac punc-
ture. Platelets were isolated by differential centrifugation,
incubated with 1.8 MBq of indium-111 oxine for 10 min,
and then repelleted, washed, and resuspended. Anesthe-
tized (urethane [25% w/v] at 10 lL g1 intraperitoneal)
recipient mice were infused with radiolabeled platelets,
and allowed to equilibrate for 15 min before collagen
(25–100 lg kg1 intravenous; Nycomed, Konstanz, Ger-
many) was injected via a femoral vein. A single point
extended area radiation detector (eV Products, Saxon-
burg, PA, USA) was fixed over the pulmonary vascular
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bed, and counts were recorded on a UCS-20 spectrometer
(Spectrum Techniques, Oak Ridge, CA, USA) with cus-
tom-made software (Mumed Systems, London, UK).
Platelet responses were then determined as an increase in
the counts in the pulmonary vascular bed associated with
the platelet agonists.
In vivo thrombus formation
In vivo thrombus formation following laser injury of the
cremaster arteriole wall was performed and analyzed as
described previously [21]. Mice were anesthetized by
intraperitoneal injection of ketamine (125 mg kg1), xyla-
zine (12.5 mg kg1), and atropine (0.25 mg kg1), and
and anesthesia was maintained with 5 mg kg1 pentobar-
bital as required through a jugular vein cannula. The cre-
master muscle was exteriorized, connective tissue was
removed, and the muscle was fixed as a single sheet over
a glass slide. Throughout this procedure, the muscle prep-
aration was hydrated with buffer (135 mM NaCl, 4.7 mM
KCl, 2.7 mM CaCl2, 18 mM NaHCO3, pH 7.4). Platelets
were labeled with Alexa Fluor 488-conjugated anti-mouse
glycoprotein (GP)Ibb antibody (0.2 lg g1 of mouse
weight) (Emfret Analytics, Eibelstadt, Germany). Injury
of the cremaster arteriole wall was induced with a Micro-
point Ablation Laser Unit (Andor Technology, Belfast,
UK). Thrombus formation was observed with an Olym-
pus BX61W1 microscope (Olympus Imaging, Southend-
on-Sea, UK) and a Hamamatsu C9300 digital camera
(Hamamatsu Photonics, Welwyn Garden City, UK), and
analyzed with SLIDEBOOK5 software (Intelligent Imaging
Innovations, Denver, CO, USA).
Statistical analysis
Data are presented as mean  standard deviation of the
mean. Statistical analyses were performed with PRISM 5
GRAPHPAD software (GraphPad Software, La Jolla, CA,
USA). Data were compared by use of a Student’s t-test
or two-way ANOVA and Bonferroni post hoc test analysis
as appropriate.
Results
Reanalysis of aggregation in platelets from KO mice dem-
onstrated that aggregation in response to a high concen-
tration of collagen (100 lg mL1) was almost entirely
abolished in KO mice as compared with Ctrl mice
(P < 0.0001) during the first 60 s, and then recovered by
300 s (Fig. 1A,B).
We have previously shown that platelets from these
mice have significantly reduced levels of both PINCH and
a-parvin [14]. To confirm that inhibition of ILK alone
causes a reduction in platelet function, and to confirm
our previous findings in humans, we used QLT0267, a
small-molecule inhibitor of the kinase-like domain of ILK
[25,26]. Although this inhibitor has been shown to effec-
tively inhibit ILK at doses ranging from 1 lM to 25 lM,
non-specific effects have been reported at high, but not
lower, concentrations [25,27]. To confirm the selectivity of
this inhibitor at a concentration previously reported to
inhibit ILK but without non-specific effects, fibrinogen
binding to CRP-XL-stimulated platelets from KO and
Ctrl mice was measured in the presence or absence of
QLT0267 (1 lM). In Ctrl mice, QLT0267 inhibited fibrin-
ogen binding at all three concentrations of CRP-XL and
across all time points (Fig. 1C). Platelets from KO mice
showed reduced fibrinogen binding as compared with Ctrl
mice, but showed no further inhibition in the presence of
QLT0267 (Fig. 1D), indicating that, at this concentration,
it is specific for ILK. Collagen-stimulated human platelets
incubated with QLT0267 showed similar inhibition of
aggregation (P = 0.0008), again characterized by complete
inhibition of aggregation in the first 45 s, accompanied by
only a moderate impairment of maximal aggregation
(Fig. 1E).
ILK inhibition also reduced the rate of clot retraction.
In the presence of QLT0267, clot retraction was inhibited
at 1.5 h but not at 3 h (Fig. 1F), consistent with reduced
‘outside-in’ signaling through aIIbb3.
We have previously shown that, although the levels of
aIIbb3 on the surfaces of unstimulated platelets from Ctrl
and KO mice are indistinguishable, following stimulation,
which leads to translocation of aIIbb3 to the platelet sur-
face, the surface expression of aIIbb3 is significantly lower
in KO than in Ctrl mice [14]. To test whether the
observed decrease in the rate of aggregation and clot
retraction following ILK inhibition or deficiency is attrib-
utable to reduced aIIbb3 surface expression or reduced
aIIbb3 activation as such, which may, in turn, lead to
reduced secretion, we assessed the activation of aIIbb3 and
surface exposure of aIIbb3 and P-selectin (a marker of
a-granule secretion) over time. Real-time flow cytometric
analysis of the rates of fibrinogen binding and P-selectin
exposure confirmed a reduction in response to the GPVI-
specific agonist CRP-XL in the presence of QLT0267.
The rate at which platelets bound fibrinogen (rate of
change in MFI) peaked at 50.8  18.3 s of stimulation,
and this rate was reduced significantly in the presence of
QLT0267 (Fig. 2A; dashed line). The rate of a-granule
release, as measured by P-selectin exposure, peaked later
than fibrinogen binding, at 103.3  19.5 s, but was simi-
larly reduced (Fig. 2B; dashed line). Although there was a
trend towards a decrease in maximum fibrinogen binding
or P-selectin exposure following treatment with QLT0267,
there was no significant difference in either (Fig. 2A,B;
solid line). As CRP-XL is a GPVI-specific agonist, this
suggests that the reduction in platelet activation is not
attributable to the involvement of ILK in a2b1 signaling.
This effect of ILK appears to be restricted to stimulation
via GPVI, as there was no observable difference in either
the rate of or maximum fibrinogen binding or P-selectin
© 2014 The Authors Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis
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exposure following treatment with QLT0267, when plate-
lets were stimulated with either ADP (Fig. 2C,D) or
thrombin (Fig. 2E,F). It is worth pointing out that ILK
may affect other aspects of thrombin-mediated platelet
activation, as QTL0267 clearly retards thrombin-induced
clot retraction (Fig. 1F), and, although KO mice did not
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Fig. 1. Deficiency or inhibition of integrin-linked kinase (ILK) reduces the rate of platelet activation. (A) Platelet aggregation in response to
collagen (100 lg mL1) was measured in mice with an induced ILK deficiency (KO) as compared with sibling matched controls (Ctrl) [14]. All
data are expressed as a percentage of Ctrl aggregation at each time point. (B) A representative trace is shown. (C, D) The binding of anti-
fibrinogen antibodies to cross-linked collagen-related peptide (CRP-XL)-stimulated platelets from (C) Ctrl and (D) KO mice was measured by
flow cytometry in the presence (red dashed line) or absence (blue line) of QLT0267 (1 lM). (E) Aggregation of collagen-stimulated
(10 lg mL1) human washed platelets was measured in the presence of the ILK inhibitor QLT0267 (1 lM) or dimethylsulfoxide (DMSO) con-
trol. All data are expressed as a percentage of aggregation in the DMSO control samples at each time point. (F) Clot retraction was measured
in the presence of QLT0267 (1 lM) or DMSO (0.025% v/v). The clotting was initiated with thrombin (1 U mL1), and a sealed glass capillary
was placed at the center of the glass test tube, around which the clot formed. Clots were removed, gently blotted to remove superficial liquid,
and then weighed after 1.5 and 3 h. In all cases: *P ≤ 0.05, ***P ≤ 0.001, n = 3. All data are presented as mean  standard deviation, and
were analyzed by two-way ANOVA with post hoc Bonferroni correction for multiple comparisons to compare treated and control samples at indi-
vidual time points. WT, wild-type.
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show an aggregation defect following thrombin stimula-
tion (Fig. S1), we have previously reported a reduction in
other aspects of thrombin-induced platelet activation in
these mice [14].
Importantly, the inhibitory effect of QLT0267 on the
rate of fibrinogen binding following CRP-XL stimulation
occurred before any measurable degranulation was
observed (Fig. 2A,B). Furthermore, there was no signifi-
cant difference between treated and untreated platelets in
the surface expression of aIIbb3 at the early time points
(0–50 s), when the rate of fibrinogen binding to activated
aIIbb3 is reduced (Fig. 2G). This demonstrates that the
reduction in the rate of fibrinogen binding to platelets is
not attributable to reduced aIIbb3 surface expression, but
to a reduction in early activation of aIIbb3. In line with
our previous data on KO mice, inhibition of ILK did
reduce the surface expression of aIIbb3 at later time points
(Fig. 2G).
To establish whether the inhibition of aIIbb3 activation
at early time points was attributable to inhibition of sig-
naling events leading to ‘inside-out’ activation of aIIbb3,
we measured calcium flux in the presence or absence of
QLT0267. Surprisingly, the inhibition of ILK with
QLT0267 led to a significant reduction in the rate of cal-
cium flux in response to CRP-XL, but had no detectable
effect on peak calcium flux (Fig. 3A). It seems unlikely
that ILK has a direct effect on signaling immediately
downstream of GPVI; instead, we hypothesized that this
inhibitory effect may be the result of reduced aIIbb3
signaling in the very earliest stages of platelet activation.
To test this, we measured calcium flux in response to
CRP-XL with or without QLT0267 in the presence of
EDTA to prevent aIIbb3 activation and isolate the GPVI-
dependent mobilization of calcium. Under these condi-
tions, ILK inhibition did not affect the rate of calcium
flux (Fig. 3B), indicating that the inhibitory effect of
QLT0267 on platelet calcium mobilization is not attribut-
able to augmentation of signaling downstream of GPVI,
but to signaling downstream of aIIbb3. The observation
that inhibition of ILK does not affect the initial rate of
platelet activation following ADP and thrombin stimula-
tion may stem from the different mechanisms by which
these agonists control the activation of RAP1 leading to
aIIbb3 activation [28,29].
Collectively, the aggregation, flow cytometry and clot
retraction data show that deficiency or inhibition of ILK
impairs the rate at which platelets can respond to stimula-
tion while only modestly inhibiting the maximal extent to
which platelets can become activated. Given the dynamic
nature of thrombus formation, it may be that a reduction
in the rate, rather than in the maximum extent, of platelet
activation is critical in regulating thrombus development.
It is, however, also conceivable that this apparently subtle
phenotype is overwhelmed and rendered inconsequential
in vivo by vascular endothelial-derived mediators (e.g.
nitric oxide or prostanoids) resulting in the limited bleed-
ing phenotype. It is worth pointing out that expression of
the Mx1 promoter is not specific to megakaryocytes, and
may therefore have unknown effects on other cell types
that account for the disparity between our previous
in vivo and in vitro data. To test these competing hypoth-
eses, we assessed platelet aggregation in vivo in Ctrl and
KO mice. Platelet aggregation in vivo was reduced signifi-
cantly in KO mice (Fig. 4). Over the range of collagen
concentrations used, both the maximum percentage
change in counts and the area under the curve were
reduced in KO mice (P < 0.0001 and P = 0.0001, respec-
tively). This demonstrates the importance of a change in
the rate of platelet activation in this more physiologic
setting. It also demonstrates that this platelet phenotype
is still functionally relevant in vivo, but raises a number
of questions. Is the reduced level of accumulation of
thrombi in the lungs attributable to a reduced platelet
response to collagen or reduced stability of the thrombi
that form? Are the effects of ILK deficiency overcome by
the high concentration of collagen at the site of injury?
The latter question may be important, given that the
reduction in platelet aggregation in KO mice was most
pronounced at intermediate concentrations of collagen,
and largely overcome at higher concentrations (Fig. 4B,C,
E,F). This may help to explain the disparity between
platelet and hemostatic responses in these mice.
To test whether thrombus stability was altered in KO
mice, and whether local collagen concentrations at the
site of injury overcome the reduction in platelet function
observed in KO mice, thereby reducing the impact of
ILK on thrombus formation, we measured thrombus for-
mation following laser injury of the cremaster arteriole
wall in Ctrl and KO mice. Thrombus formation was
altered significantly in KO mice (Fig. 5A–D; Fig. S2).
Although there was no statistical difference between Ctrl
and KO mice in the sum fluorescence intensity of thrombi
(a measure of the total platelet mass recruited to the site
of injury) or the thrombus area (a measure of thrombus
size) at any time point, or between the maxima of these
measures (Fig. 5C,D), there were noticeable differences
between their thrombi. Notably, the thrombi in KO mice
were unstable, forming, embolizing and reforming contin-
uously (Fig. 5A, Fig. S2). It is this instability that, at
later time points, leads to the apparent greater thrombus
size in KO mice, which is the result of multiple unstable
thrombi forming and embolizing out of phase with each
other (Fig. 5C,D; Fig. S2B). Methods to quantify throm-
bus stability in this system have not been described. To
capture, in a quantifiable manner, this important readout
of thrombus stability, we developed a new method that
allowed us to assess the stability of thrombi. The throm-
bus instability index (TII) measures the standard devia-
tion of data immediately preceding each time point to
quantify changes (growth, retraction, or embolization) in
thrombus size. Ctrl mice had a characteristic double-
peaked TII trace. TII increased as thrombi grew in
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Fig. 2. Reduction in the rate of aIIbb3 activation is not attributable to reduced aIIbb3 surface expression. (A–F) Real-time measurements of
fibrinogen binding (A, C, E) and P-selectin exposure (B, D, F) in response to cross-linked collagen-related peptide (CRP-XL) (1 lg mL1)
(A, B), thrombin (C, D) and ADP (E, F) were made by flow cytometry following incubation of human platelet-rich plasma with QLT0267
(1 lM) or dimethylsulfoxide (DMSO) control. In both cases, solid lines with shaded areas show the LOESS curve of the median fluorescence
intensity (MFI) and standard deviation (plotted on the left-hand axis), and the dashed lines show the rate of change of the LOESS curve (plot-
ted on the right-hand axis). (G) Surface expression of aIIbb3 on human platelets stimulated with CRP-XL (1 lg mL
1) in the presence (red line)
or absence (blue line) of QLT0267 (1 lM). **P ≤ 0.01, ***P ≤ 0.0001, n = 3 or n = 4. All data are presented as mean  standard deviation,
and were analyzed by two-way ANOVA with post hoc Bonferroni correction for multiple comparisons to compare treated and control samples at
individual time points.
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response to injury, decreased as thrombus size reached its
maximum and plateaued, increased again during retrac-
tion, and then showed a sustained period of stability (low
TII) resulting from the formation of a stable hemostatic
thrombus (Fig. 5E, top panel). In contrast, thrombi form-
ing in KO mice showed greater instability, growing to a
similar size as those of Ctrl mice but then embolizing,
growing again, and embolizing repeatedly. This was
clearly observed by the extension of peaks in the TII trace
from KO mice into the third and fourth minute after
laser injury (Fig. 5E, bottom panel). Thus, in KO mice,
TII remained high over the 4-min measurement period,
and was significantly higher than in Ctrl mice after 2 min
(Fig. 5F). Clearly, ILK deficiency and the associated
reduction in the rate of platelet activation does not pre-
vent thrombus formation, but it does significantly alter
the development and stability of thrombus formation.
Discussion
We set out to examine the role of ILK in regulating the
rate of platelet activation and thrombus formation, in an
effort to understand the previously reported disparity
between the reduced platelet function and the only modest
increase in bleeding in mice with an induced ILK defi-
ciency. We confirmed that inhibition of ILK reduced the
rates of both fibrinogen binding and a-granule secretion in
response to CRP-XL but not ADP or thrombin, and dem-
onstrated that the reduced rate of fibrinogen binding was a
consequence of reduced aIIbb3 activation rather than
reduced translocation of aIIbb3 to the platelet surface. Inhi-
bition of ILK resulted in a reduced rate of clot retraction
(indicating reduced ‘outside-in’ signaling) and a reduction
in the rate of calcium flux that was driven by signaling
downstream of aIIbb3, not GPVI. The reduced rate of
platelet activation was accompanied by only moderate
reduction of the maximum extent of platelet activation or
aggregation in vitro. However, absence of ILK led to a
reduction in platelet aggregation in vivo, and a marked
increase in the instability of thrombi. Taken together, these
findings indicate that, although ILK is not essential for
platelet activation, it plays a critical role in facilitating
timely platelet activation, which is essential for stable
thrombus formation. This deeper understanding of the role
of ILK provides an explanation for previous findings.
Mice with systemically induced ILK deficiency do have a
defect in thrombus development, as would be expected,
given the impairment of platelet function, but they still
form thrombi and hence prevent excessive bleeding.
Thrombus formation is a highly dynamic, sequential pro-
cess, and it is therefore intuitive that the rate at which plate-
lets become activated during this process will have a
significant impact on thrombus size and structure. The
results for KO mice clearly demonstrate this effect. It is par-
ticularly interesting that ILK deficiency does not prevent
thrombus formation, as can be seen in CalDEG-GEFI-
deficient mice, in which the rate of platelet activation is also
impaired [28–30], but instead alters the stability of thrombi
that form. In interpreting this difference, it is important to
note that: (i) although the maximum rate of activation is
reduced in Figs 2 and 3, the very earliest responses to CRP-
XL (the time at which the first detectable response can be
seen and the very earliest rate of response) are the same
with or without ILK inhibition; and (ii) the rate of fibrino-
gen binding and P-selectin expression in response to ADP
and thrombin are unaffected by ILK inhibition.
Together, these data suggest a scenario in which, in the
absence of ILK or following ILK inhibition, platelets
adhere to the site of injury and become activated by col-
lagen. This is supported by our previous findings that the
surface exposure of a2b1 or GPVI is not altered in ILK-
deficient platelets, and neither is the initial adhesion of
platelet to collagen [14]. Full activation of these initially
adherent platelets is, however, delayed, as shown by
reductions in the rate of calcium flux, aIIbb3 activation,
degranulation, and clot retraction. Subsequent platelets
binding to these partially activated platelets will react
normally to stimulation by thrombin and ADP, leading
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response to cross-linked collagen-related peptide (1 lg mL1) in the
(A) absence or (B) presence of EDTA were made by flow cytometry
following incubation of human platelet-rich plasma with QLT0267
(1 lM) or dimethylsulfoxide (DMSO) control. In both cases, solid
lines with shaded areas show the LOESS curve of the median fluo-
rescence intensity (MFI) and standard deviation (plotted on the left-
hand axis), and the dashed lines show the rate of change of the
LOESS curve (plotted on the right-hand axis). n = 4. All data are
presented as mean  standard deviation.
© 2014 The Authors Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis
1348 C. I. Jones et al
to thrombus formation. We hypothesize that, as the
thrombus grows, the force exerted on the initial, collagen-
activated platelets at the base of the thrombus will
increase. The delay in full activation of these platelets
renders the thrombus unstable, as the force exerted on
these platelets becomes greater than the strength of the
bonds between the platelets, leading to embolization.
It is clear that relatively subtle changes in the dynamics
of platelet activation can have a profound effect on
thrombus formation, and it is perhaps worth speculating
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that components of signaling pathways that regulate the
rates of different aspects of platelet activation or alter the
rates of activation to differing degrees may have pro-
foundly different effects on thrombus formation.
Previous studies have shown that ILK effects both inte-
grin activation and downstream signaling [2,31]. The data
presented here suggest that in platelets these two facets of
ILK are linked. Thus, that upon collagen receptor stimu-
lation, the effect of ILK in enhancing ‘outside-in’ signal-
ing at early (< 60 s) time points acts as a positive
feedback loop that enhances the rate of calcium flux and
further ‘inside-out’ aIIbb3 activation. Modulation of the
rate of aIIbb3 activation in the presence of QLT0267,
which is a selective inhibitor of the serine/threonine
kinase domain of ILK, suggests that this domain is
important. The role of ILK as a kinase is controversial
[32]; however, it is through the kinase domain that ILK
binds to parvin, paxillin, c-Src, and others [33–35]. It is
therefore possible that QLT0267 disrupts the ability of
ILK to act as an adaptor protein, possibly altering the
role of the IPP complex in regulating Ras and Rho family
GTPases, modulation of which has been shown to alter
00:00:00.000
00:00:00.000
4×106
3×106
3×106
8×107
6×107
4×107
2×107
0
2×106
2×106
1×106
1×106
0
0
3×106
2×106
1×106
0
Su
m
 fl
uo
re
sc
en
ce
 in
te
ns
ity
 (U
)
Th
ro
m
bu
s 
in
st
ab
ilit
y 
in
de
x 
(U
)
AU
C 
of
 th
ro
m
bu
s 
in
st
ab
ilit
y 
in
de
x 
(U
)
Th
ro
m
bu
s 
a
re
a
 (p
ixe
ls
)
0 30 60 90 120 150 210 240180
00:00:30.199
00:00:29.900 00:00:59.762 00:01:29.957 00:02:00.144 00:02:30.009 00:02:59.873 00:03:30.094 00:03:59.922
00:01:00.036 00:01:29.870 00:02:00.075 00:02:29.910 00:02:59.854 00:03:30.059 00:03:59.890
Time (s)
0 30 60 90 120 150 210 240180
0 30 60 90 120 150 210 240180
Time (s)
0
0
60–120 120–180180–2400–60
7500
5000
2500
30 60 90 120 150 210 240180
Time (s)
Time (s)
Ctrl
Ctrl
Ctrl
KO
Ctrl
KO
KO
KO
* *
A
B
C
E
F
D
Fig. 5. Induced integrin-linked kinase (ILK) deficiency increases thrombus instability. (A, B) Representative images of thrombus formation fol-
lowing laser injury of the cremaster arteriole wall of (A) control (Ctrl) and (B) knockout (KO) mice measured over a period of 4 min. (C, D)
There was no significant difference in (C) the sum fluorescence intensity or (D) the area of thrombi formed in KO and Ctrl mice. The shaded
area shows the standard deviation about the mean. KO, n = 4; Ctrl, n = 3; an average of 4.6 thrombi were generated per mouse. (E, F) Quanti-
fication of the stability of thrombi that formed in these mice by use of a thrombus instability index (standard deviation of data immediately
preceding each time point) (E) identified prolonged instability in the thrombi of KO mice as compared with Ctrl mice (F). In all cases:
*P ≤ 0.05. All data are presented as mean  standard deviation, and were analyzed by t-test. AUC, area under the curve.
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the rate of platelet activation and thrombus stability
[30,36]. Another potential consequence of ILK inhibition
or deficiency may be reduced kindlin activation. The
interaction of ILK with kindlin has been shown to be an
important step in regulating the conformational change
of kindlin that precipitates its binding to b-integrins [37],
which, in concert with the binding of talin, leads to acti-
vation of aIIbb3. Whichever of these mechanisms is
responsible for ILK-mediated regulation of aIIbb3, it is
interesting to note that the effects of inhibiting ILK could
only be observed following stimulation with collagen or
CRP-XL, and not in response to ADP or thrombin. This
difference may relate to the mechanisms by which GPVI
and the G-protein-coupled receptors regulate the activa-
tion of talin and hence ‘inside-out’ signaling, and their
relative reliance on feedback mechanisms (such as ‘out-
side-in’ signaling) to fully activate the large numbers of
aIIbb3 molecules on the platelet surface. Teasing apart the
relative importance of these mechanisms and their impact
on different agonist pathways will be the focus of future
work.
We conclude that ILK has a role in regulating the rate
of the platelet response to collagen via GPVI. Inhibition
or deficiency of ILK reduces the rate at which platelets
activate and form stable aggregates. The physiologic con-
sequences of this are a reduction in thrombus stability
and an inability to form tight hemostatic thrombi in a
timely manner.
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